Samuel Funt, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Samuel Funt, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07390617 · A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial CarcinomaMemorial Sloan Kettering Cancer Center · recruiting · Neuropathy, Urothelial Carcinoma, Metastatic Urothelial Carcinoma · principal investigator
- Ph2NCT03430895 · Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary TractMemorial Sloan Kettering Cancer Center · completed · Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder · principal investigator
- Ph2NCT03158064 · Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsMemorial Sloan Kettering Cancer Center · active not recruiting · Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma · principal investigator
- Ph2NCT03093922 · A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerMemorial Sloan Kettering Cancer Center · completed · Urothelial Carcinoma, Locally Advanced, Unresectable · principal investigator
- Ph1/Ph2NCT02989584 · A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma · principal investigator
- Ph2NCT02553642 · Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)Memorial Sloan Kettering Cancer Center · completed · Bladder Cancer, Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.